Borderline Ovarian Epithelial Tumor Active Not Recruiting Phase 2 Trials for Selumetinib (DB11689)

IndicationStatusPhase
DBCOND0078954 (Borderline Ovarian Epithelial Tumor)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00551070Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum CancerTreatment